GTCR Announces Sale Of Cord Blood Registry To AMAG

CHICAGO--(BUSINESS WIRE)--GTCR, a leading private equity firm, announced that its portfolio company Cord Blood Registry (“CBR” or the “Company”) has signed a definitive agreement to be acquired by AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty pharmaceutical company that focuses on maternal health and hematology, for $700 million. The transaction is expected to close in the third quarter upon the receipt of regulatory approvals and satisfaction of other customary conditions.

Help employers find you! Check out all the jobs and post your resume.